Prof. Paul Peter Tak Amsterdam University Medical Centre, The Netherlands

Paul-Peter Tak is currently CEO of Kintai Therapeutics (Cambridge, MA), Professor of Medicine at the Amsterdam University Medical Centre (AMC), Honorary Professor of Rheumatology at Ghent University and Honorary Senior Visiting Fellow at the University of Cambridge. He received his medical degree cum laude from the Free University in Amsterdam... read moreand was trained as an internist, rheumatologist and immunologist at Leiden University Medical Center, where he also received his PhD. He has worked as a scientist at the University of California San Diego. He served as Professor of Medicine and founding Chair of the Department of Clinical Immunology and Rheumatology at the Academic Medical Centre/University of Amsterdam (AMC). His research group discovered the role of the cholinergic anti-inflammatory pathway in rheumatoid arthritis (RA), a chronic immune-mediated inflammatory disease. At GlaxoSmithKline he served as global head of Research & Development for ImmunoInflammation, Infectious Disease and Oncology; Development Leader; and Chief Immunology Officer. He has published extensively in peer-reviewed journals (568 publications; H factor 122 [Google Scholar]) and served on numerous editorial boards. He received the Medal of Honour from the Netherlands Society for Rheumatology, was elected ‘Toparts Reumatologie’ (Elected by peers as ‘Best Rheumatologist’ in the Netherlands based on his clinical work), was awarded Honorary Membership by the European League Against Rheumatism and has been elected Fellow of the Academy of Medical Sciences in the UK.